Emrelis wins FDA approval, marking ABBV's first lung cancer drug and strengthening its oncology reach into solid tumors.

Broad effectiveness forms part of Genmab’s argument that Rina-S can improve on AbbVie’s Elahere, an approved ADC against the same target. AbbVie has sued Genmab over Rina-S, accusing the ...

In addition, mirvetuximab soravtansine (Elahere) was the first targeted therapy to demonstrate an improvement in OS in ...

RTX carries a strong balance sheet with a BBB+ credit rating from S&P. This is supported by $5.2 billion in cash on hand, and ...

Results of the trial, which evaluated the efficacy and safety of mirvetuximab soravtansine-gynx (Elahere, AbbVie), were presented at Society of Gynecologic Oncology Annual Meeting on Women’s Cancer.

Toon Van Gorp, MD, PhD, discusses the rationale behind and the findings from the phase 3 MIRASOL trial of mirvetuximab ...

North Chicago, Illinois-based AbbVie Inc. (ABBV) discovers, develops, manufactures, and sells pharmaceuticals worldwide. With ...

AbbVie's Elahere has been shown to reduce the risk of death in patients with folate receptor-alpha (FRα) positive, platinum-resistant ovarian cancer by a third, reinforcing its blockbuster ...

AbbVie's $10.1 billion takeover of ImmunoGen has been rewarded with EU approval for Elahere, the first drug specifically cleared for folate receptor-alpha (FRα) positive, platinum-resistant ...

Pharmaceutical stocks often outperform during market downturns because they pay dividends and their products are mostly necessities. AbbVie ( ABBV 0.02%) is one of the best. It outperformed the ...

Solid results were also seen in the neuroscience and oncology segments, with Elahere standing out by bringing in $179 million in global revenue. A major driver of this success was the positive ...